TOP
Skip to the content
THANC Foundation
    • About Us
          • Board of Directors
          • Staff
          • Contact Us
          • Financials
            • Form 990 (2021)
            • Form 990 (2020)
            • Form 990 (2019)
          • Press Materials
            • Donor Privacy Policy
          • 2022 Year in Review
          • News
          • Events
          • 30 Stories in 30 Days™
            • Share Your Story
          • Faces of Courage™
          • Videos
          • Photo Gallery
    • Our Mission
          • For Patients
            • The Cancer Journey
            • Eating Healthy & Treating Cancer
            • Prevention Starts with #BetterHabits
            • FAQs
            • Resources
            • SPOHNC
          • EL-PFDD: Xerostomia
            • Xerostomia - Voice of the Patient Report
            • Xerostomia - Online Comments
            • Xerostomia EL-PFDD Meeting Info
          • Research
            • Research List
            • Head & Neck Articles
            • Thyroid Articles
            • Transoral Robotic Surgery (TORS)
          • Join Our Team
            • Fellows
            • Research Associates
            • Gutierrez Scholar
            • Observers
            • OMFS Residency Program
          • Major Initiatives
            • THANC Guide
            • TIRO
          • THANC’s Mission

          • We are committed to supporting research and education in the early detection and treatment of thyroid and head and neck cancer; to advancing new therapeutic approaches; and to alleviating the suffering and functional impairment of patients who undergo treatment.

    • Shop
    • Give Today
          • Give Your Change
          • Connect a card to round-up your purchases to the next dollar and donate your change.

          • Donate Now
          • By making a donation today, you can help us do more with our research and reach further with our online resources.

          • Donate Monthly
          • For as little as $10 a month, you can become a sustaining member of research and fund the future of medicine.

          • The THANC Foundation is a 501(c)(3) non-profit organization (Federal Tax ID 80-0062118). Your contribution will be tax-deductible under the fullest extent of the law.

          • Start a Fundraiser
          • Browse Fundraisers
          • Account Login
          • 9 Ways to Support THANC
            • 3 Steps to Create a Fundraiser
            • Make THANC Your GoodShop Charity
            • Estate Planning
    • About Us
          • Board of Directors
          • Staff
          • Contact Us
          • Financials
            • Form 990 (2021)
            • Form 990 (2020)
            • Form 990 (2019)
          • Press Materials
            • Donor Privacy Policy
          • 2022 Year in Review
          • News
          • Events
          • 30 Stories in 30 Days™
            • Share Your Story
          • Faces of Courage™
          • Videos
          • Photo Gallery
    • Our Mission
          • For Patients
            • The Cancer Journey
            • Eating Healthy & Treating Cancer
            • Prevention Starts with #BetterHabits
            • FAQs
            • Resources
            • SPOHNC
          • EL-PFDD: Xerostomia
            • Xerostomia - Voice of the Patient Report
            • Xerostomia - Online Comments
            • Xerostomia EL-PFDD Meeting Info
          • Research
            • Research List
            • Head & Neck Articles
            • Thyroid Articles
            • Transoral Robotic Surgery (TORS)
          • Join Our Team
            • Fellows
            • Research Associates
            • Gutierrez Scholar
            • Observers
            • OMFS Residency Program
          • Major Initiatives
            • THANC Guide
            • TIRO
          • THANC’s Mission

          • We are committed to supporting research and education in the early detection and treatment of thyroid and head and neck cancer; to advancing new therapeutic approaches; and to alleviating the suffering and functional impairment of patients who undergo treatment.

    • Shop
    • Give Today
          • Give Your Change
          • Connect a card to round-up your purchases to the next dollar and donate your change.

          • Donate Now
          • By making a donation today, you can help us do more with our research and reach further with our online resources.

          • Donate Monthly
          • For as little as $10 a month, you can become a sustaining member of research and fund the future of medicine.

          • The THANC Foundation is a 501(c)(3) non-profit organization (Federal Tax ID 80-0062118). Your contribution will be tax-deductible under the fullest extent of the law.

          • Start a Fundraiser
          • Browse Fundraisers
          • Account Login
          • 9 Ways to Support THANC
            • 3 Steps to Create a Fundraiser
            • Make THANC Your GoodShop Charity
            • Estate Planning

Clinical Trial Finder

Search Results

GIST Oral Paclitaxel(Liporaxel)

Study Purpose

The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 20 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Age 20 years or older, at the time of acquisition of informed consent. 2. Histologically confirmed metastatic and/or advanced GIST with CD117(+), DOG-1(+), or mutation in KIT or PDGFRα gene. 3. Failed (progressed and/or intolerable) after prior treatments for GIST, including at least imatinib and sunitinib, regorafenib. 4. Adequate tissue obtained after treatment failure to imatinib, sunitinib, and regorafenib for P-glycoprotein immunohistochemistry (IHC) analysis, and showed P-glycoprotein expression of less than 6. (For patients with PDGFRα D842V mutation or other subtypes with poor response to tyrosine kinase inhibitors, tumor tissue obtained at any period can be used.) 5. Eastern Cooperative Oncology Group (ECOG) performance status 0~2. 6. Resolution of all toxic effects of prior treatments to grade 0 or 1 by NCI-CTCAE version 5.0. 7. At least one measurable lesion as defined by RECIST version 1.1. 8. Adequate bone marrow, hepatic, renal, and other organ functions.
  • - Neutrophil >1,500/mm3.
  • - Platelet > 100,000/mm3.
  • - Hemoglobin >8.0 g/dL.
  • - Total bilirubin < 1.5 x upper limit of normal (ULN) - AST/ALT < 2.5 x ULN.
  • - Creatinine <1.5 x ULN.
9. Life expectancy > 12 weeks. 10. Washout period of previous TKIs or chemotherapy for more than 4 times the half life ((Imatinib and regorafenib need 1 week and sunitinib need 2 weeks.) 11. Provision of a signed written informed consent.

Exclusion Criteria:

1. Women of child-bearing potential who are pregnant or breast feeding. 2. Women or men who are not willing to use effective contraception entering the study period or until at least 3 months after the last study drug administration. 3. If any of the following applies within ≤ 6 months prior to starting study enrollment : Myocardial Infarction, severe instable angina, coronary/peripheral bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack, treatment required severe arrhythmia. 4. Uncontrolled infection. 5. Diabetes mellitus with clinically significant peripheral artery disease. 6. Acute and chronic liver disease and all chronic liver impairment.(But Patients with stable chronic hepatitis B are eligible) 7. Uncontrolled gastrointestinal toxicities with toxicity greater than NCI CTCAE grade 2. 8. Acute, or chronic medical or psychiatric condition or laboratory abnormality such as active uncontrolled infection that difficult to study participation in the judgment of the investigator. 9. The patient experienced any bleeding episode considered life-threatening, or any grade 3 or 4 bleeding event. (required transfusion or endoscopic or surgical intervention) 10. Patient who underwent major surgery or is under recovery from surgery within 28 days from the study treatment. 11. Known diagnosis of HIV infection (HIV testing is not mandatory). 12. History of another primary malignancy that is currently clinically significant or currently requires active intervention. 13. Patients with clinically suspected brain metastasis symptom, brain metastases as assessed by radiologic imaging. 14. Alcohol or substance abuse disorder. 15. Known severe hypersensitivity to paclitaxel. 16. Received paclitaxel-based treatment for GIST

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT06326346
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Asan Medical Center
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Not yet recruiting
Countries Korea, Republic of
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Gastrointestinal Stromal Tumors
Additional Details

The survival outcomes of patients with advanced and/or metastatic gastrointestinal stromal tumors (GIST) have markedly improved with application of imatinib, the KIT tyrosine kinase inhibitor (GlivecTM, Novartis) for the treatment. Recently, sunitinib (SuteneTM, Pfizer) and regorafenib (StivargaTM, Bayer) have shown efficacy in patients with disease progression on imatinib as second- and third-line treatment, respectively. However, most patients develop acquired resistance to KIT tyrosine kinase inhibitors and show disease progression. While cytotoxic chemotherapeutic agents were expected to have minimal antitumor effect on GIST, recent preclinical studies have shown that 37 out of 89 different chemotherapeutic agents have shown antitumor effects on at least one or more GIST cell lines. Especially, topoisomerase II inhibitors, paclitaxel, bortezomib have shown promising results. Based on the results, the investigators conducted a single center, single arm phase II study to evaluate efficacy and safety of paclitaxel for patients with GIST who failed to prior imatinib and sunitinib. Overall efficacy was modest, although patients with low P-glycoprotein expression showed better efficacy compared to those with high P-glycoprotein expression. Subsequently, the investigators performed another phase 2 trial to evaluate efficacy of paclitaxel for previously treated GIST patients with low P-glycoprotein expression and have met the primary endpoint. Liporaxel is an oral formulation of paclitaxel, and showed high bioavailability, safety, and antitumor effect from non-clinical studies. From a phase 1 clinical trial for metastatic solid tumor patients, Liporaxel showed adequate PK/PD profiles. Compared to intravenous paclitaxel, administration is relatively easier and has better safety in terms of hypersensitivity reaction which is caused by the admixture of intravenous formulation of paclitaxel. From a multicenter phase 3 trial conducted in South Korea for patients with advanced gastric adenocarcinoma who failed on first-line palliative chemotherapy (DREAM trial), Liporaxel showed non-inferiority compared to intravenous paclitaxel in terms of both safety and efficacy, and it is currently approved for the second-line treatment in advanced gastric cancer. Also, Liporaxel proved safety and potential efficacy in patients with HER2 negative metastatic breast cancer as first-line chemotherapy, and currently multicenter phase 3 trial in ongoing (OPTIMAL3 trial). The purpose of this study is to evaluate safety and efficacy of Liporaxel for patients with GIST who failed on prior standard treatments, including imatinib, sunitinib, and regorafenib, and with low P-glycoprotein expression.

Arms & Interventions

Arms

Experimental: Oral Paclitaxel (Liporaxel)

Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)

Interventions

Drug: - Liporaxel

Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Seoul, Songpagu, Korea, Republic of

Status

Address

Asan Medical Center, University of Ulsan College of Medicine

Seoul, Songpagu, 138-736

Site Contact

Min-Hee Ryu, MD, PhD

[email protected]

82-2-3010-5936

Nearest Location

Site Contact

Min-Hee Ryu, MD, PhD

[email protected]

82-2-3010-5936


Resources

This is placeholder for the THANC Foundation to update

Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with a healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with site contacts or other relevant parties. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage trial participants to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

The THANC Foundation is a 501(c)(3) charitable organization.

Federal Tax ID 80-0062118.

Follow us on Social Media

THANC’s Mission

We are committed to supporting research and education in the early detection and treatment of thyroid and head and neck cancer; to advancing new therapeutic approaches; and to alleviating the suffering and functional impairment of patients who undergo treatment.

Copyright © 2023 THANC Foundation

  • Donate
  • Login
  • About THANC
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • THANC Guide
  • TIRO
This website uses cookies to ensure you get the best experience on our website. Learn moreGot it!
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Cookie Duration Description
CONSENT 16 years 4 months 21 days 7 hours 17 minutes These cookies are set via embedded youtube-videos. They register anonymous statistical data on for example how many times the video is displayed and what settings are used for playback.No sensitive data is collected unless you log in to your google account, in that case your choices are linked with your account, for example if you click “like” on a video.
vuid 2 years This domain of this cookie is owned by Vimeo. This cookie is used by vimeo to collect tracking information. It sets a unique ID to embed videos to the website.
_ga 2 years This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gat_UA-26689388-1 1 minute This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.
_gid 1 day This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Cookie Duration Description
IDE 1 year 24 days Used by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
test_cookie 15 minutes This cookie is set by doubleclick.net. The purpose of the cookie is to determine if the user's browser supports cookies.
VISITOR_INFO1_LIVE 5 months 27 days This cookie is set by Youtube. Used to track the information of the embedded YouTube videos on a website.
YSC session This cookies is set by Youtube and is used to track the views of embedded videos.
yt-remote-connected-devices never These cookies are set via embedded youtube-videos.
yt-remote-device-id never These cookies are set via embedded youtube-videos.
yt.innertube::nextId never These cookies are set via embedded youtube-videos.
yt.innertube::requests never These cookies are set via embedded youtube-videos.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Cookie Duration Description
charitable_session 1 day No description available.
cookielawinfo-checkbox-functional 1 year The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
debug never No description available.
socialsnap_viewed_1052 session No description
socialsnap_viewed_1057 session No description
socialsnap_viewed_1205 session No description
socialsnap_viewed_1253 session No description
socialsnap_viewed_1294 session No description
socialsnap_viewed_13 session No description
socialsnap_viewed_1374 session No description
socialsnap_viewed_177 session No description
socialsnap_viewed_1888 session No description
socialsnap_viewed_1889 session No description
socialsnap_viewed_1890 session No description
socialsnap_viewed_1958 session No description
socialsnap_viewed_201 session No description
socialsnap_viewed_205 session No description
socialsnap_viewed_207 session No description
socialsnap_viewed_209 session No description
socialsnap_viewed_211 session No description
socialsnap_viewed_213 session No description
socialsnap_viewed_217 session No description
socialsnap_viewed_2195 session No description
socialsnap_viewed_2197 session No description
socialsnap_viewed_2199 session No description
socialsnap_viewed_2201 session No description
socialsnap_viewed_2203 session No description
socialsnap_viewed_2205 session No description
socialsnap_viewed_2207 session No description
socialsnap_viewed_221 session No description
socialsnap_viewed_2227 session No description
socialsnap_viewed_225 session No description
socialsnap_viewed_227 session No description
socialsnap_viewed_2353 session No description
socialsnap_viewed_26 session No description
socialsnap_viewed_2654 session No description
socialsnap_viewed_2656 session No description
socialsnap_viewed_2659 session No description
socialsnap_viewed_2678 session No description
socialsnap_viewed_271 session No description
socialsnap_viewed_2796 session No description
socialsnap_viewed_293 session No description
socialsnap_viewed_3022 session No description
socialsnap_viewed_305 session No description
socialsnap_viewed_307 session No description
socialsnap_viewed_3071 session No description
socialsnap_viewed_309 session No description
socialsnap_viewed_31 session No description available.
socialsnap_viewed_3121 session No description
socialsnap_viewed_33 session No description
SAVE & ACCEPT
Powered by CookieYes Logo